Market Overview

Why The Novartis-AveXis Deal Is Good News For The Gene Therapy Space

Share:
Why The Novartis-AveXis Deal Is Good News For The Gene Therapy Space
Related NVS
The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs
Benzinga's Top Upgrades, Downgrades For November 26, 2018
Tencent Music, Starbucks And Under Armour In Focus (Stocks To Watch Podcast) (Seeking Alpha)
Related
Benzinga's Daily Biotech Pulse: Portola Receives FDA Nod, Mallinckrodt Gets Thumbs Down
Benzinga's Daily Biotech Pulse: SIGA Rallies On FDA Panel Backing, Rigel And Gilead React To Earnings

AveXis Inc (NASDAQ: AVXS) announced Monday its sale to Novartis AG (ADR) (NYSE: NVS) for $8.7 billion, or $218 per share.

The deal didn’t come as a complete surprise.

The Rating

Chardan analyst Gbola Amusa maintained a Buy rating on AveXis and increased the price target from $140 to $218.

The Thesis

Amusa previously predicted AveXis’ acquisition on the basis of faith in the firm’s lead candidate, AVXS-101, the analyst said. Separately, he anticipated Novartis’ emergence as a consolidator in the AAV-based gene therapy space.

The combined prophecies are expected to merge with the deal’s closure in mid-2018, and Amusa forecast a couple implications for the industry.

For one, Novartis will have proven its position as a consolidator in genetic medicine, the analyst said. 

“We expect Novartis to acquire or partner further in AAV-based ophthalmology gene therapy," Amusa said in a Monday note. He mentioned Spark Therapeutics Inc (NASDAQ: ONCE), Nightstar Therapeutics PLC (NASDAQ: NITE) or Regenxbio Inc (NASDAQ: RGNX) as potential targets.

At the same time, the process and final price to secure AveXis is considered an industry positive.

“An 88-percent premium to us suggests other parties were bidding on AveXis, which to us means unfulfilled demand for GT assets,” the analyst said. “We believe the price paid also reflects a supportive view by Novartis on the risk of systemic toxicity for AAV-based gene therapies.”

Novartis plans to issue a tender offer by April 17.

Price Action

AveXis popped after hours on the news and, at time of publication, traded up 82 percent off Friday’s close to $209.60 a share.

Related Links:

Solid Biosciences Snags Bullish Initiation As It Develops Gene Therapy For Muscular Dystrophy

5 Reasons Why Vuzix Is One Of Chardan Capital's Top Picks In 2018

Latest Ratings for NVS

DateFirmActionFromTo
Nov 2018Cowen & Co.UpgradesMarket PerformOutperform
Nov 2018Goldman SachsUpgradesNeutralConviction Buy
Sep 2018CitigroupUpgradesNeutralBuy

View More Analyst Ratings for NVS
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech News Health Care Price Target Reiteration M&A Top Stories Best of Benzinga

 

Related Articles (NITE + AVXS)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
BAPItau BBAUpgrades274.0
DVNJP MorganDowngrades37.0
EOGJP MorganUpgrades118.0
EQMBarclaysDowngrades48.0
EXPDGoldman SachsDowngrades68.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Benzinga's Top Upgrades, Downgrades For April 9, 2018

The Market In 5 Minutes: Deutsche Bank, GM, Trump, WrestleMania And More